More Videos
SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Gold Retreats from Record High as Dollar Rebounds
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- China Unveils Carbon Target Ahead of Copenhagen
- UK's Darling to Downgrade 2009 Growth Forecast
- Hyundai-Kia Targets Rapid China Growth in 2010
- No Thanksgiving Rest for Retailers in Sales Race
- Fannie Mae to Tighten Lending Standards: Report
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- US Markets Bracing for Selloff on Dubai Debt Worries
- US Dollar Falls to 14-Year Low Against the Yen
- No Thanksgiving Rest for Retailers in Sales Race
- UK's Darling to Downgrade 2009 Growth Forecast
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
Researchers looked at all sorts of cardiovascular medications including cholesterol fighters, also known as statins. The top-selling statin--the top-selling drug in the world, for that matter--is Lipitor from Pfizer [PFE
Loading...
()
]. The pill rakes in around $13 billion a year, but sales growth has stalled since Zocor from Merck [MRK
Loading...
()
]went generic and companies, doctors and insurers started putting more patients on the cheaper alternative. The new JAMA study, which included clinical trials of generic Zocor, could presumably spur that trend.
PhRMA the drug industry's main lobbying organization, put out a statement late yesterday on the JAMA study saying, "The contention that brand-name medicines drive up the cost of health care is fatally flawed. Without today's innovative brand-name drugs to legally copy, there would be no generic drug industry. Worse yet, there would be little hope of finding new treatments and cures for a wide range of debilitating--and often deadly--diseases."
You expect a group like PhRMA to take a defensive position. That's its job. But I was surprised when this press release from Pfizer popped up in the inbox this morning (see link below) only hours after the JAMA study came out.
The communication touts the results of another study being published in "Mayo Clinic Proceedings" showing that Lipitor works 13 percent better than generic Zocor in preventing heart attacks, stroke, etc. The senior VP of Pfizer's global medical division, Dr. Michael Berelowitz, is quoted as saying, "The latest analysis adds to the wealth of real-world data from a number of different medical database analyses that suggest that patients who are treated with Lipitor may have a reduced risk of experiencing a cardiovascular event compared with patients who use simvastatin."
Simvastatin is the scientific, generic name for Zocor. And to drive home the point, the Dr. Berelowitz statement finishes with, "Findings such as these should be taken into account by those who may assume that medicines in a therapeutic class are interchangeable and provide similar outcomes."
That's an interesting opinion to be voiced so close on the heels of a much more prominent JAMA study that draws the exact opposite conclusion.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes